Table 2 Clinical characteristics on admission
Variables | All patients | Survival | Death | p-value |
|---|---|---|---|---|
Subject, n | 68 | 50 | 18 | |
Respiratory conditions | ||||
Oxygen flow, L/min | 3 (2–10) | 3 (2–10) | 5 (3–10) | 0.12 |
Serological findings | ||||
White blood cell count, × 103 /μL | 8.2 (6.6–10.5) | 8.1 (6.6–10.4) | 9.6 (6.4–10.5) | 0.70 |
Neutrophils count, × 103 /μL (n = 66) | 6.78 (4.53–8.65) | 6.49 (4.49–8.80) | 7.56 (5.37–8.54) | 0.68 |
Lymphocytes, count, × 103 /μL (n = 66) | 0.94 (0.69–1.25) | 1.03 (0.76–1.25) | 0.66 (0.43–1.35) | 0.11 |
Hemoglobin, g/dL | 10.8 (9.8–12.5) | 10.7 (9.8–12.5) | 11.2 (9.7–12.5) | 0.95 |
Platelet count, × 103 /μL | 198 (132–267) | 206 (157–258) | 179 (88.8–328) | 0.68 |
LDH, IU/L | 292 (243–379) | 280 (238–363) | 345 (269–388) | 0.21 |
BUN, mg/dL | 21.6 (16.1–32.7) | 20.2 (15.9–30.6) | 25.2 (18.5–34.9) | 0.12 |
eGFR, mL/min | 51.2 (40.8–67.8) | 60.6 (43.4–71.9) | 43.2 (29.8–50.9) | < 0.05 |
CRP, mg/dL | 8.63 (3.82–13.5) | 8.54 (3.48–13.2) | 10.3 (7.77–14.2) | 0.25 |
BALF findings | ||||
Total cell counts in BALF, × 104 /μL | 5.2 (3.1–9.4) | 5.1 (3.1–8.8) | 5.4 (3.9–10.8) | 0.79 |
Neutrophils percentage in BALF, % | 32.0 (13.1–47.0) | 23.5 (7.35–38.8) | 58.8 (41.9–70.4) | < 0.05 |
Lymphocytes percentage in BALF, % | 19.5 (8.9–39.9) | 25.3 (13.0–50.6) | 8.75 (6.1–12.8) | < 0.05 |
Clinical courses | ||||
Time from onset to admission, days | 4 (2–7) | 4 (2–9) | 4 (2–5) | 0.68 |
Time from admission to diagnosis of DAH, days | 1 (0–3) | 1 (0–3) | 1 (0–3) | 0.95 |
Treatments | ||||
Invasive ventilation, n | 38 (56%) | 22 (44%) | 16 (89%) | < 0.05 |
Non-invasive ventilation, n | 9 (13%) | 8 (16%) | 1 (5.6%) | 0.23 |
Administration of antibiotics, n | 57 (84%) | 39 (78%) | 18 (100%) | < 0.05 |
Administration of corticosteroids, n | 56 (82%) | 40 (80%) | 16 (89%) | 0.49 |